Young, Andrea S.
Arnold, L. Eugene
Wolfson, Hannah L.
Fristad, Mary A.
Funding for this research was provided by:
National Institute of Mental Health (R34 MH85875)
Article History
First Online: 8 September 2016
Compliance with Ethical Standards
:
: Dr. Young has received research funding from Psychnostics, LLC. Dr. Arnold has received research funding from Curemark, Forest, Lilly, Neuropharm, Novartis, Noven, Shire, Supernus, and YoungLiving (as well as NIH and Autism Speaks) and has consulted with or been on advisory boards for Arbor, Gowlings, Ironshore, Neuropharm, Novartis, Noven, Organon, Otsuka, Pfizer, Roche, Seaside Therapeutics, Sigma Tau, Shire, Tris Pharma, and Waypoint. Dr. Fristad receives royalties from Guilford Press, American Psychiatric Press and CFPSI for treatment manuals, workbooks and a diagnostic instrument reported on in this study and honoraria from Physician’s Post-Graduate Press and the American Occupational Therapy Association.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Informed consent/assent was obtained from all individual participants included in the study.